ASIA PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUG MARKET FORECAST 2017-2025

ASIA PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUG MARKET FORECAST 2017-2025

  • September 2017 •
  • 65 pages •
  • Report ID: 5118328
KEY FINDINGS
The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 8.99% during the forecast period of 2017-2025. The market worth is expected to increase from $797 million in 2016 and reach $1708 million by 2025. The ease of the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.

MARKET INSIGHTS
The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide, and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.

COMPETITIVE INSIGHTS
Shionogi & Co.Ltd, Daiichi Sankyo Co Ltd, Nektar Therapeutics, Ono Pharmaceutical Co.Ltd, Mundipharma International Limited, Takeda Pharmaceutical Company Limited, Daewoong Pharmaceutical Co and Cosmo Pharmaceuticals are few of the eminent companies in this market.